The Zhitong Finance App learned that Changfeng Pharmaceutical (02652) rose nearly 8% in early trading. As of press release, it rose 4.58% to HK$6.4, with a turnover of HK$18.266,900.

According to the news, the latest data from the Hong Kong Stock Exchange shows that on October 6, Chairman and CEO Leung Man-ching increased his holdings of Changfeng Pharmaceutical by 193,000 shares, at a price of HK$6.9216 per share, for a total amount of about HK$133,600. The latest number of shares held after the increase was approximately 607.16,500 shares, with a shareholding ratio of 18.74%.

Notably, Dr. Liang Wenqing, Chairman of the Board, Executive Director and CEO, and Dr. Li Li, the company's co-founder, executive director and chief scientific officer, recently made a voluntary commitment to further extend the ban period for 6 months after the original ban expires on October 7. The sales ban will be extended from October 8, 2026 to April 7, 2027.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.